RT Journal Article SR Electronic T1 Safety and acceptability of clozapine and risperidone in progressive multiple sclerosis: a phase 1, randomized, blinded, placebo-controlled trial JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.03.12.20034983 DO 10.1101/2020.03.12.20034983 A1 Anne Camille La Flamme A1 David Abernethy A1 Dalice Sim A1 Liz Goode A1 Michelle Lockhart A1 David Bourke A1 Imogen Milner A1 Toni-Marie Garrill A1 Purwa Joshi A1 Eloise Watson A1 Duncan Smyth A1 Sean Lance A1 Bronwen Connor YR 2020 UL http://medrxiv.org/content/early/2020/03/16/2020.03.12.20034983.abstract AB Objective Because clozapine and risperidone have been shown to reduce neuroinflammation in humans and mice, the CRISP trial was conducted to determine whether clozapine and risperidone are suitable for progressive multiple sclerosis (pMS).Methods The CRISP trial (ACTRN12616000178448) was a blinded, randomized, placebo-controlled trial with three parallel arms (n=12/arm). Participants with pMS were randomized to clozapine (100 to 150 mg/day), risperidone (2 to 3.5 mg/day), or placebo for six months. The primary outcome measures were safety (adverse events/serious adverse events) and acceptability (TSQM-9).Results An interim analysis (n=9) revealed significant differences in the time-on-trial between treatment groups and placebo (p=0.030 and 0.025, clozapine and risperidone, respectively) with all participants receiving clozapine being withdrawn during the titration period (mean dose=35±15 mg/day). Participants receiving clozapine or risperidone reported a significantly higher rate of adverse events than placebo (p=0.00001) but not serious adverse events. Specifically, low doses of clozapine appeared to cause an acute and dose-related intoxicant effect in patients with pMS, who had fairly severe chronic spastic ataxic gait and worsening over all mobility, which resolved on drug cessation.Interpretation The CRISP trial results suggest that pMS patients may experience increased sensitivity to clozapine and risperidone and indicate that the dose and/or titration schedule developed for schizophrenia may not be suitable for pMS. While these findings do not negate the potential of these drugs to reduce MS-associated neuroinflammation, they highlight the need for further research to understand the pharmacodynamic profile and effect of clozapine and risperidone in pMS patients.Competing Interest StatementACL and BC have a patent for the use of clozapine and risperidone during MS. The authors declare no other financial interests.Clinical TrialACTRN12616000178448Funding StatementThis study was funded by a grant from the New Zealand Ministry for Business, Innovation, and Employment (RTVU1503 to ACL, DA, and BC) and donations from the Great New Zealand Trek Charitable Trust (to ACL). The funders of this study did not have any role in study design, data collection, statistical analysis, or interpretation. Douglas Pharmaceuticals provided the study medications and provided the initial advice regarding their use, but did not contribute funds or play a role in data collection, statistical analysis, or interpretation.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified data collected during this study and presented in this manuscript are available from the corresponding author on request from individuals affiliated with research or health care institutions.